Earnings Call · Q1 FY2023·2023-05-12

Q1 23EPS +4.94%·Rev n/aQ4 22EPS +24.75%·Rev n/aQ3 22EPS -15.75%·Rev n/aQ2 22EPS +4.07%·Rev n/a⚠ consensus missing

LISATA THERAPEUTICS, INC. LSTA

John Menditto — Unknown

David Mazzo — Chief Executive Officer

James Nisco — Chief Financial Officer

Kristen Buck — Executive (likely Chief Medical Officer or similar)

−0.5%1d on move date−0.9% vs SPY3d+0.9%5d+3.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LSTA calls or request research access.

More LSTA calls Browse calls Request research access